Edwards Lifesciences Corporation provided sales guidance for the first quarter of 2020 and revised sales guidance for the year 2020. For the first quarter of 2020, the company projects total sales to be between $1.15 and $1.2 billion.

The company provided that 2020 sales guidance for the company is now expected to be $4.6 to $5.0 billion versus the company's previous range of $4.5 to $5.0 billion.

The company recorded a impairment of long-lived assets of $40.6 million charge in the fourth quarter ended December 31, 2019 and a $116.2 million charge in the fourth quarter of 2018 related to the other-than-temporary impairment of certain developed technology and in-process research and development acquired as part of the acquisition of Valtech Cardio Ltd.